Delphia (USA)’s Quest Diagnostics DGX Stock Holding History

Delphia (USA)’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,813	Closed	-$248K	–	416
2022 Q1	$248K	Buy	1,813 +538	+42%	+$75K	0.19%	208
2021 Q4	$221K	Buy	+1,275	New	+$194K	0.23%	188

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Delphia (USA)'s DGX Position: Q2 2022 in Review

Delphia (USA) sold out of Quest Diagnostics (DGX) in Q2 2022, closing a stake of 1,813 shares — an estimated $248K sold.

Delphia (USA) first reported a position in DGX in Q4 2021 and held it in 2 quarters. The position peaked at $248K in Q1 2022. 851 funds tracked by Wall St. Rank hold DGX as of Q2 2022.

Delphia (USA) reported no remaining Quest Diagnostics position as of Q2 2022 after selling out during the quarter.
Delphia (USA) sold 1,813 Quest Diagnostics shares in Q2 2022, an estimated $248K.
Delphia (USA) first reported a position in Quest Diagnostics in Q4 2021 and held it in 2 quarters.
Delphia (USA)'s Quest Diagnostics position peaked at $248K in Q1 2022.
851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2022.

Based on Delphia (USA)'s 13F filing for Q2 2022, filed 15 Aug 2022.